Citius Oncology Issues Warrants in Private Placement
I'm PortAI, I can summarize articles.
Citius Oncology (CTOR) announced the issuance of warrants for 360,000 shares of common stock as part of a private placement, with exercise set for March 2026. The board also amended its 2024 Omnibus Stock Incentive Plan, increasing authorized shares from 15 million to 30 million. Analyst ratings for CTOR stock are mixed, with a Buy rating and a $3.00 price target, while Spark's AI Analyst rates it as Neutral, citing financial challenges and a low P/E ratio that suggests potential undervaluation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments